AB CHMINACA is an indazole-based manufactured cannabinoid. It is a powerful agonist of the CB1 receptor (Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM) and completely substitutes for Δ9-THC in rodent separation thinks about, while being 16x more strong. Proceeding with the pattern seen in different cannabinoids of this age, it contains a valine amino corrosive amide buildup as a component of its structure, where more seasoned cannabinoids contained a naphthyl or adamantane deposit.
AB CHMINACA is a logical reference standard arranged as an engineered cannabinoid. This item is expected for investigate and legal applications.
AB CHMINACA, or N-[(2S)- 1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide, is a manufactured indazole cannabinoid tranquilize as it contains a substituted indazole center. A cyclohexylmethyl gather is bound to this indazole center at R1 of the indazole. This indazole is substituted at R3 with a carboxamide gathering. The terminal amine of this carboxamide is clung to a substituted propyl chain with an aminocarbonyl aggregate at R1 and a methyl amass at R2.
Abdominal muscle CHMINACA (N-[(2S)- 1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide) is a medication that goes about as an intense agonist for the cannabinoid receptors which produces subjective impacts to some degree. It was created by Pfizer and unveiled in a 2009 patent as a potential pain relieving drug, yet was never sought after for human utilize.
This product is intended for research and forensic applications. Warning - this product is not for human or veterinary use.
A crystalline solid
210, 303 nm
Warning - this product is not for human or veterinary use.